GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
LEXICON PHARMACEUTCL (LXRX) [hlAlert]

Rating:
Buy LXRX
down 25.62 %

LEXICON PHARMACEUTCL (LXRX) rated Buy by Jefferies

Posted on: Thursday,  May 30, 2013  8:25 AM ET by Jefferies

Jefferies rated Buy LEXICON PHARMACEUTCL (NASDAQ: LXRX) on 05/30/2013, when the stock price was $16.31. Since
then, LEXICON PHARMACEUTCL has lost 25.63% as of 01/04/2016's recent price of $12.13.
If you would have followed this Jefferies's recommendation on LXRX, you would have lost 25.62% of your investment in 949 days.

Lexicon Pharmaceuticals, Inc. (Lexicon), is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a diverse pipeline of drug targets behind its clinical programs with many compounds and antibodies in preclinical research. Lexicon is conducting clinical trials for four drug candidates, with its most advanced program in Phase II clinical trials.

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/30/2013 8:25 AM Buy
None
16.31
as of 12/13/2013
1 Week down  -12.00 %
1 Month down  -22.12 %
3 Months down  -20.00 %
1 YTD down  -24.46 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy